Concert Pharmaceuticals (NASDAQ:CNCE)‘s stock had its “hold” rating reiterated by investment analysts at Mizuho in a research note issued on Tuesday. They currently have a $23.00 target price on the biotechnology company’s stock. Mizuho’s price target would suggest a potential upside of 7.83% from the company’s previous close.

A number of other equities research analysts have also weighed in on CNCE. ValuEngine raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub raised Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, February 9th. Zacks Investment Research raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Concert Pharmaceuticals in a research note on Friday, November 10th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $30.00 target price on shares of Concert Pharmaceuticals in a research note on Sunday, October 22nd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Concert Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $24.33.

Shares of Concert Pharmaceuticals (NASDAQ:CNCE) opened at $21.33 on Tuesday. Concert Pharmaceuticals has a 52 week low of $9.04 and a 52 week high of $30.71.

In other Concert Pharmaceuticals news, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $26.65, for a total transaction of $34,188,112.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard Aldrich sold 11,946 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $20.89, for a total value of $249,551.94. Following the transaction, the director now directly owns 286,975 shares of the company’s stock, valued at approximately $5,994,907.75. The disclosure for this sale can be found here. In the last three months, insiders sold 1,433,248 shares of company stock valued at $37,226,329. 10.10% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in Concert Pharmaceuticals by 57.2% during the 4th quarter. BlackRock Inc. now owns 1,786,223 shares of the biotechnology company’s stock valued at $46,210,000 after purchasing an additional 649,808 shares during the last quarter. Ingalls & Snyder LLC raised its position in Concert Pharmaceuticals by 8.7% during the 4th quarter. Ingalls & Snyder LLC now owns 1,314,562 shares of the biotechnology company’s stock valued at $34,008,000 after purchasing an additional 105,500 shares during the last quarter. Vanguard Group Inc. raised its position in Concert Pharmaceuticals by 11.0% during the 2nd quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock valued at $10,553,000 after purchasing an additional 74,801 shares during the last quarter. Millennium Management LLC raised its position in Concert Pharmaceuticals by 225.8% during the 4th quarter. Millennium Management LLC now owns 725,885 shares of the biotechnology company’s stock valued at $18,779,000 after purchasing an additional 503,066 shares during the last quarter. Finally, Lyon Street Capital LLC raised its position in Concert Pharmaceuticals by 6.5% during the 3rd quarter. Lyon Street Capital LLC now owns 463,064 shares of the biotechnology company’s stock valued at $6,830,000 after purchasing an additional 28,312 shares during the last quarter. 67.44% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Concert Pharmaceuticals (CNCE) Given “Hold” Rating at Mizuho” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/15/concert-pharmaceuticals-cnce-given-hold-rating-at-mizuho.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.